Baseline characteristics of patients who underwent liver transplantation for an autoimmune disease in Canada, 2000–2018
| Characteristic | Group; no. (%) of patients* | p value | ||
|---|---|---|---|---|
| Primary biliary cholangitis n = 341 | Primary sclerosing cholangitis n = 489 | Autoimmune hepatitis n = 220 | ||
| Age of recipient, median (Q1–Q4), yr | ||||
| Overall | 56 (48–61) | 45 (35–53) | 48 (33–58) | < 0.001 |
| Female | 55 (47–61) | 45 (34–54) | 48 (35–59) | < 0.001 |
| Male | 58 (51–64) | 44 (35–53) | 49 (32–57) | |
| Sex of recipient | < 0.001 | |||
| Female | 277 (81.2) | 137 (28.0) | 153 (69.5) | |
| Male | 64 (18.8) | 352 (72.0) | 67 (30.4) | |
| Age of donor, median (Q1–Q4), yr | 42 (28–54) n = 338 | 39 (28–53) n = 477 | 43 (30–52) n = 208 | 0.8 |
| Sex of donor | 0.003 | |||
| Female | 180 (53.4) | 200 (41.8) | 105 (50.5) | |
| Male | 157 (46.6) | 278 (58.2) | 103 (49.5) | |
| Missing | 4 (1.2) | 11 (2.2) | 12 (5.4) | |
| Donor type | 0.07 | |||
| DCD | 13 (3.8) | 19 (3.9) | 10 (4.5) | |
| NDD | 243 (71.3) | 331 (67.7) | 170 (77.3) | |
| LDLT | 85 (24.9) | 139 (28.4) | 40 (18.2) | |
| MELD score, median (Q1–Q4) | 18 (13–24) n = 216 | 18 (13–24) n = 295 | 18 (14–28) n = 143 | 0.2 |
| Creatinine level, median (Q1–Q4), μmol/L | 77 (59–105) n = 227 | 73 (61–102) n = 307 | 78 (62–98) n = 147 | 0.5 |
| Bilirubin level, median (Q1–Q4), μmol/L | 92 (41–280) n = 216 | 115 (48–281) n = 297 | 74 (43–317) n = 143 | 0.3 |
| INR, median (Q1–Q4) | 1.4 (1.2–1.8) n = 217 | 1.4 (1.2–1.8) n = 297 | 1.7 (1.4–2.3) n = 145 | < 0.001 |
DCD = donation after cardiac death; INR = International Normalized Ratio; LDLT = living donor liver transplantation; MELD = Model for End-stage Liver Disease; NDD = neurologic determination of death; Q = quartile.
↵* Except where noted otherwise.